REGENERON PHARMACEUTICALS NASDAQ: REGN
Background of Regeneron Pharmaceuticals
- Regeneron Pharmaceuticals, Inc. is an American-based biotechnology company which dates its history back to 1988, giving it 33 years in the pharmaceuticals industry.
- Regeneron Pharmaceuticals, Inc. was initially focused on neurotrophic factors as well as their regenerative capabilities, which led to the company’s name, and beyond this, Regeneron Pharmaceuticals, Inc. also included the study of cytokine and tyrosine kinase receptors in its research portfolio.
- Regeneron Pharmaceuticals, Inc. was responsible for the development of aflibercept which is a VEGF inhibitor as well as rilonacept, which is an interleukin-1 blocker.
- VEGF is a protein which typically stimulates the growth of blood vessels while interleukin-1 is a protein typically involved with inflammation.
- In 2012, Bloomberg announced that Sanofi and Regeneron Pharmaceuticals, Inc. were collaborating in the development for a new drug which would reduce cholesterol up to 72% more than competitors, targeting the PCSK9 gene.
- In 2015, Regeneron Pharmaceuticals, Inc. announced a new global collaboration involving Sanofi to discover, develop, and commercialise new immune-oncology drugs, which would generate more than $2 billion (29.7 billion ZAR), with an amount of $650 million (9.4 billion ZAR) upfront, $750 million (10.9 billion ZAR) for proof-of-concept data, and the last $650 million (9.4 billion ZAR) from the development of REGN2810.
- REGN2810 was eventually renamed cemiplimab and in 2019, Regeneron Pharmaceuticals, Inc. was announced the 7th best stock of the 2010s, having achieved a total return of 1,457%.
- In 2017, Regeneron Pharmaceuticals, Inc. entered a deal with the United States Government’s Biomedical Advanced Research and Development Authority, where the government would fund 80% of costs for Regeneron Pharmaceuticals, Inc. to develop and manufacture antibody treatments, including that for Coronavirus disease 2019, with Regeneron Pharmaceuticals, Inc. retaining the right to set the prices and control production.
- This deal received a lot of criticism in The New York Times. However, such deals are common for routine drug development in the pharmaceutical market.
- In 2025 Regeneron Pharmaceuticals, Inc. announced that it would repurchase shares to the value of $5 billion (72.9 billion ZAR) which consisted of 23.2 million shares held directly by Sanofi.
- Today, Regeneron Pharmaceuticals, Inc. has more than 9,100 employees and the company has operations based around the globe.
- In July 2025, under “Operation Warp Speed”, Regeneron Pharmaceuticals, Inc. was granted a $450 million (6.5 billion ZAR) government contract to manufacture and supply its experimental treatment REGN-COV2, which is an artificial “antibody cocktail” which was undergoing clinical trials as a potential treatment for those who have contracted Covid-19.
- It was also intended for use to prevent SARS-CoV-2 coronavirus infections from occurring.
- The funds provided came from the Biomedical Advanced Research and Development Authority (BARDA) as well as the DoD Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defence, and lastly, the Army Contracting Command.
- Regeneron Pharmaceuticals, Inc. anticipated the production of between 70,000 to 300,000 treatment doses or between 420,000 to 1.3 million preventative doses.
- The US Government reported that in funding the manufacturing effort, the federal government will own the doses which are expected to result from the demonstration project.
- However, in its own new release the same day, Regeneron Pharmaceuticals, Inc. stated that the government committed to making doses from the lots available to the American people free of charge and would subsequently be responsible for distribution, noting that it would depend on the government granting emergency use authorisation or product approval.
Regeneron Pharmaceuticals Shares Growth Driver
- Regeneron Pharmaceuticals, Inc. is a successful pharmaceutical company that owes its success to strategic collaborations and its participation in research for Covid-19.
- In February 2025, the United States Department of Health and Human Services, already working with Regeneron Pharmaceuticals, Inc., announced that the pharmaceutical company would start pursuing monoclonal antibodies to fight the Covid-19 virus.
- In October 2025, when former US President Donald Trump, was infected with Covid-19, he was taken to Walter Reed National Military Medical Centre in Maryland and received REGN-COV2. It was obtained from Regeneron Pharmaceuticals, Inc. through a compassionate use request.
- On October 7, Regeneron Pharmaceuticals, Inc. filed with the FDA for emergency use authorisation and in the filing, it was specified that there were 50,000 doses and Regeneron Pharmaceuticals, Inc. anticipated to reach a goal of 300,000 doses in a few months.
- Regeneron Pharmaceuticals, Inc. received emergency use authorisation from the FDA in November 2025.
- Regeneron Pharmaceuticals, Inc. has an extensive portfolio of marketed products which includes Arcalyst, Eylea, Zaltrap, Praluent, Dupixent, Kevzara, Libtayo, and Inmazeb.
- Regeneron Pharmaceuticals, Inc. novel and patented “Trap Technology” creates high-affinity product candidates for a wide range of signalling molecules, which includes growth factors as well as cytokines.
- This trap technology consists of the fusion of two distinct fully human receptor components as well as a fully human immunoglobulin-G constant region.
- In addition to this, Regeneron Pharmaceuticals, Inc. has also developed a suite of patented technologies which allow its scientists to determine the best targets for therapeutic intervention, rapidly generating high-quality, fully human antibodies drug candidates to address these targets.
Regeneron Pharmaceuticals Investor Tip
- Regeneron Pharmaceuticals, Inc. trades its shares on the NASDAQ Stock Market (NASDAQ) under the stock symbol REGN. Regeneron Pharmaceuticals, Inc. forms part of both the NASDAQ-100 and the S&P 500
- An analysis on the market performance for the first quarter of 2025, reported on May 6, indicate that revenues increased by 38% to $2.35 billion (34.2 billion ZAR) versus the first quarter of 2025.
- The first quarter 2025 GAAP diluted earnings per share was $10.9 (158.64 ZAR).
- Regeneron Pharmaceuticals, Inc. also reported positive data from Phase 3 trials with REGEN-COV which is used to treat and prevent Covid-19.
- This shows that Regeneron Pharmaceuticals, Inc. showed strong performance during the first quarter, especially in the fight against Covid-19.
- In addition to this, Regeneron Pharmaceuticals, Inc. also expects continued growth with EYLEA in treating retinal diseases along with Dupixent through further penetration in existing indications, followed by a broad Phase 3 development program.
- In oncology, Regeneron Pharmaceuticals, Inc. finds itself in the early days of launching Libtayo for advanced basal cell carcinoma as well as non-small cell lung cancers. This also includes recently announced positive pivotal data in cervical cancer with regulatory submissions which are planned for later in the year.
- Regeneron Pharmaceuticals, Inc. is expected to experience strong performance during the remaining quarters, with clear bottom-line growth as result of solid execution across the business, positioning Regeneron Pharmaceuticals, Inc. for sustainable long-term growth.
- Data from the analysis should be weighed against forecasted performance during this pandemic, but for now, prices on shares and in turn dividends remain unaffected, which provides shareholders with assurance that they will have a strong buy-in on NASDAQ.
Sector
Healthcare
Industry
Biotechnology
Sub industry
Pharmaceuticals
Latest News
Regeneron Pharmaceuticals: How to buy Regeneron Pharmaceuticals Shares Online
Here are the steps you need to follow to buy Regeneron Pharmaceuticals, Inc. shares with utmost confidence:
- Navigate to the AvaTrade website and select ‘Register’.
- Complete the registration form with the required information and submit documentation to verify your proof of Identity along with your proof of address.
- As soon as your account application has been reviewed and approved, you can select your trading platform from AvaTrade’s website, or by visiting the MetaTrader 4 or MetaTrader 5 websites respectively to start download.
- Once you have downloaded the trading platform of your choice, you can use your AvaTrade live account details to log into your AvaTrade account on the trading platform.
- From the Market Watch screen on both MetaTrader 4 and MetaTrader 5, you can select ‘REGN’ to buy/purchase shares.
- Alternatively, you can make use of AvaTrade’s online Web Trader or the AvaTradeGo mobile application.
Trading CFDs and Stocks with AvaTrade provides traders with the following benefits:
- Leverage of up to 1:20.
- Being able to trade stocks on the NYSE, NASDAQ, FTSE, and various others.
- Indices, stocks, and commodities can all be traded form a single screen.
- Client support is presented live in a multitude of languages.
- Traders have exclusive access to a variety of educational tools.
- Trades can be executed across multiple platforms.
More shares that can be purchased through AvaTrade, can be viewed here.
FAQ
Can I buy Regeneron Pharmaceuticals, Inc. shares in South Africa?
Yes, you can.
How to buy Regeneron Pharmaceuticals, Inc. shares?
By simply opening a free account with SA Shares, or by clicking the “Buy this Share” button to get started.
What is the current share price?
By clicking on the link provided above, you can view the real-time Regeneron Pharmaceuticals, Inc. share price on the platform.
Is Regeneron Pharmaceuticals, Inc. a good share to buy?
Yes, it is. Regeneron Pharmaceuticals, Inc. is a good share to buy especially with its involvement in treating and preventing Covid-19.
Can I buy Regeneron Pharmaceuticals, Inc. CFD through SA Shares?
Yes, you can.
Top 4 Brokers
